A group of Finnish researchers have planned a new trial to investigate whether population-based screening for prostate cancer is justifiable if a mortality benefit can be proven with a substantial reduction in rates of over-treatment.
The trial will be known as the ProScreen trial and is designed to enroll about 67,000 men aged between 55 and 67 years at study entry. The trial will involve multiple forms of patient evaluation to lower risk for over-treatment.
The “New” Prostate Cancer InfoLink is currently seeking a copy of the full text of the paper by Auvinen et al. so that we can be sure we are describing this trial with accuracy.
Be warned, this trial will probably not report results before about 2030 at the very earliest!
Filed under: Diagnosis, Management, Risk | Tagged: Management, outcome, screening, Treatment, trial |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply